Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05367492 · ClinicalTrials.gov registry record · Phase 4
Varenicline for Nicotine Vaping Cessation in Adolescents
A Phase 4 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 4
- Development phase
- 261
- Enrollment target
NCT05367492: Completed Phase 4 study, sponsored by Massachusetts General Hospital.
NCT05367492 is a Phase 4 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 261 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05367492, a Phase 4 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 261 participants
- Enrollment target
Study Summary
The study will test the hypothesis that varenicline, when added to behavioral and texting support for vaping cessation, will improve vaping abstinence rates in adolescents dependent on vaped nicotine over placebo plus behavioral and texting support for vaping cessation. Approximately 225 adolescents will be randomly assigned to one of three arms (1) varenicline up to 1 mg bid for 12 weeks plus behavioral and texting support for vaping cessation (V+BC), (2) identical appearing placebo plus behavioral and texting support (P+BC) and (3) enhanced usual care (EUC). The primary comparison will be the double-blind, placebo-controlled comparison of vaping cessation rates in those assigned to varenicline vs placebo.
Interventions
- BEHAVIORAL QuitVaping
- DRUG Double Blind Placebo
- DRUG Double Blind Varenicline
- BEHAVIORAL This Is Quitting
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 261 participants |
| Start Date | 2022-06-22 |
| Est. Completion | 2024-05-28 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05367492
The ClinicalTrials.gov registry entry for NCT05367492 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 261 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which QuitVaping is the first listed.
NCT05367492 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05367492 about?
NCT05367492 is a clinical study titled "Varenicline for Nicotine Vaping Cessation in Adolescents". The study will test the hypothesis that varenicline, when added to behavioral and texting support for vaping cessation, will improve vaping abstinence rates in adolescents dependent on vaped nicotine over placebo plus behavioral and texting support for vaping cessation. Approximately 225 adolescents...
What is the current status of trial NCT05367492?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 261 participants. The study started on 2022-06-22. Estimated completion is 2024-05-28.
What interventions are being tested in trial NCT05367492?
The interventions under investigation include: QuitVaping (BEHAVIORAL), Double Blind Placebo (DRUG), Double Blind Varenicline (DRUG), This Is Quitting (BEHAVIORAL).
Who is sponsoring clinical trial NCT05367492?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.